The abstract is read at the publisher; the summary is JClub's.
Early weight loss with incretin-based obesity pharmacotherapy provides prognostic information, but it should not be used to define treatment response.
- Why it matters: Clinicians need a better way to characterize how patients respond to incretin-based obesity drugs beyond early scale changes, including health effects and real-world feasibility.
- What they did: The authors propose a multidimensional framework that combines the pattern and magnitude of weight reduction with effects on anthropometric and cardiometabolic indices, tolerability, and adherence to the treatment response phenotype.
- The result: This approach reframes treatment response so early weight loss is prognostic context rather than the sole definition, supporting more comprehensive response assessment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.